



## Bioengineering of Biotherapeutics

Guest Editor:

**Dr. Hanieh Khalili**  
School of biomedical science,  
University of West London,  
London W5 5RF, UK

Deadline for manuscript  
submissions:  
**closed (25 November 2022)**

### Message from the Guest Editor

Dear Colleagues,

*Bioengineering* is currently soliciting manuscripts for a Special Issue focusing on novel manufacturing methods (recombinant or chemical methods) to develop antibody-based therapeutics. Manuscripts can include literature reviews as well as primary research papers. Topics of particular interest include platforms for discovery/development of antibodies, antibody fragments, bispecific antibodies, and antibody–drug conjugates. Different strategies for manufacturing, characterization, and formulation of biotherapeutic with focus on purity, yield, and binding are particularly encouraged.





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Anthony Guiseppi-Elie**

Department of Biomedical  
Engineering, Texas A&M  
University, College Station, TX  
77843, USA

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

**Journal Rank:** JCR - Q2 (*Engineering, Biomedical*)

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

## Contact Us

*Bioengineering* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/bioengineering](http://mdpi.com/journal/bioengineering)  
[bioengineering@mdpi.com](mailto:bioengineering@mdpi.com)  
[X@Bioeng\\_MDPI](https://twitter.com/Bioeng_MDPI)